BIOMAT Database Logo BIOMAT Database Logo

Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease. 2021

Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China.

TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure-activity relationships (SARs) of 3-(4-(2-((1H-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors. Among them, compound 14l exhibited acceptable TYK2 inhibition with an IC50 value of 9 nM, showed satisfactory selectivity characteristics over the other three homologous JAK kinases, and performed good functional potency in the JAK/STAT signaling pathway on lymphocyte lines and human whole blood. In liver microsomal assay studies, the clearance rate and half-life of 14l were 11.4 mL/min/g and 121.6 min, respectively. Furthermore, in a dextran sulfate sodium colitis model, 14l reduced the production of pro-inflammatory cytokines IL-6 and TNF-α and improved the inflammation symptoms of mucosal infiltration, thickening, and edema. Taken together, 14l was a selective TYK2 inhibitor and could be used to treat immune diseases deserving further investigation.

UI MeSH Term Description Entries
D008297 Male Males
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003106 Colon The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON. Appendix Epiploica,Taenia Coli,Omental Appendices,Omental Appendix,Appendices, Omental,Appendix, Omental
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D005765 Gastrointestinal Agents Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. Digestants,Gastric Agents,Gastric Drugs,Gastrointestinal Drugs,Agents, Gastric,Agents, Gastrointestinal,Drugs, Gastric,Drugs, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor.
May 2020, Journal of medicinal chemistry,
Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
Crystal structure of 3-{5-[3-(4-fluoro-phen-yl)-1-isopropyl-1H-indol-2-yl]-1H-pyrazol-1-yl}indolin-2-one ethanol monosolvate.
March 2016, Acta crystallographica. Section E, Crystallographic communications,
Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
2-(4-Chloro-phen-yl)-4-[1-(4-chloro-phen-yl)-3-methyl-1H-pyrazol-5-yl]-5-methyl-1H-pyrazol-3(2H)-one.
September 2010, Acta crystallographica. Section E, Structure reports online,
Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
2-[(5-Amino-3-methyl-1-phenyl-1H-pyrazol-4-yl)(4-chloro-phen-yl)meth-yl]malononitrile.
April 2008, Acta crystallographica. Section E, Structure reports online,
Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
2-[3-(4-Methoxyphen-yl)-1-phenyl-1H-pyrazol-5-yl]phenol.
February 2009, Acta crystallographica. Section E, Structure reports online,
Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
4-(1H-pyrazol-1-yl)-2-butylamine derivatives as inhibitors of blood platelet aggregation.
May 1989, Farmaco (Societa chimica italiana : 1989),
Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
December 2016, Journal of medicinal chemistry,
Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
1,5-Dimethyl-4-{[1-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl-idene)eth-yl]amino}-2-phenyl-1H-pyrazol-3(2H)-one.
June 2010, Acta crystallographica. Section E, Structure reports online,
Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C.
September 2019, ACS medicinal chemistry letters,
Chufeng Zhang, and Wenyan Qi, and Yong Li, and Minghai Tang, and Tao Yang, and Kongjun Liu, and Yong Chen, and Dexin Deng, and Mingli Xiang, and Lijuan Chen
4-[5-Amino-4-(4-fluoro-phen-yl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl]benzo-nitrile.
April 2012, Acta crystallographica. Section E, Structure reports online,
Copied contents to your clipboard!